Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRHYTHM Biosciences Ltd

RHYTHM Biosciences Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.069 AUD -0.00 ( 1.43%)
Last update at 2026-11-06T04:52:00Z
VOLUME
80339
Market Cap
24.77M

Momentum Score

…

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.07
Low
0.07
High
52 Week Price Range
0.06
Low
0.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

RHYTHM Biosciences Ltd is an Australian medical diagnostics company focused on developing and commercialising non-invasive screening tests for colorectal cancer and related conditions. Long-term growth may be driven by increased screening uptake, aging populations, and successful commercial rollouts and reimbursement in domestic and international markets. The company appears positioned to benefit from demand for earlier, less-invasive cancer detection and potential recurring revenue from test deployment.
Key investment risks include clinical validation challenges, intense competition from established screening methods, execution risk in scaling commercial operations, and potential funding shortfalls.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.07
Dividend Yield
-
Revenue TTM
1.74M
Revenue Per Share
0.01
Gross Profit TTM
1.33M
Debt / Equity
0.07
ROE
-276.00%
Net Debt
-3.11M
ROCE
-199.70%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -7.51M -3.83M -8.55M -8.22M -8.79M
Net income -5.93M -3.83M -6.86M -8.22M -6.32M
Selling general administrative 5.95M 1.67M 1.41M 7.33M 5.33M
Selling and marketing expenses - 3.45M 1.59M 0.18M 0.56M
Gross profit -4.40M 2.97M -1.36M -0.33M -0.17M
Reconciled depreciation 0.19M - 0.20M 0.19M 0.10M
Ebit -7.46M -3.73M -8.54M -11.54M -11.25M
Ebitda -7.27M -3.53M -8.35M -11.35M -11.14M
Depreciation and amortization 0.19M 0.20M 0.20M 0.19M 0.10M
Operating income -7.46M -3.53M -6.71M -11.54M -11.25M
Other operating expenses 7.54M 6.72M 8.40M 11.54M 11.25M
Interest expense 0.07M 0.07M 0.00M - 0.02M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.08M 0.07M 0.05M 0.23M 0.02M
Net interest income 0.00M - 0.05M 0.23M 0.02M
Income tax expense -1.58M - -1.69M -0.23M -2.48M
Total revenue 0.09M 3.19M 1.69M 0.23M 0.02M
Total operating expenses 3.06M 6.50M 5.35M 11.54M 11.25M
Cost of revenue 4.48M 0.22M 3.05M 0.56M 0.20M
Total other income expense net -0.05M -0.30M -1.84M 3.10M 2.45M
Net income from continuing ops -5.93M - -6.86M -8.22M -8.79M
Net income applicable to common shares - -3.83M -6.86M -8.22M -8.79M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 4.78M 2.83M 1.52M 7.70M 8.44M
Intangible assets 0.28M 0.32M - 0.39M 0.43M
Other current assets 0.24M 0.19M 0.09M 0.12M 0.09M
Total liab 1.14M 2.17M 0.65M 1.82M 1.07M
Total stockholder equity 3.64M 0.66M 0.87M 5.87M 7.37M
Other current liab 0.54M 0.52M 0.27M 0.35M 0.57M
Common stock 44.96M 37.75M 34.45M 31.55M 27.83M
Capital stock 44.96M - - 31.55M 27.83M
Retained earnings -48.43M -42.50M -38.67M -31.82M -23.60M
Other liab - - - 0.06M 0.05M
Good will 0.53M 0.53M - - -
Other assets - - 0.00M - -
Cash 3.36M 1.40M 0.71M 4.12M 7.55M
Total current liabilities 1.04M 2.16M 0.56M 1.77M 0.93M
Net debt -3.11M -0.29M -0.55M -4.04M -7.38M
Short term debt 0.17M 1.11M 0.08M 0.08M 0.09M
Short long term debt 0.09M - - - -
Short long term debt total 0.25M 1.11M 0.16M 0.08M 0.17M
Other stockholder equity - - - 6.14M 3.14M
Property plant equipment - - - 0.10M 0.24M
Total current assets 3.76M 1.81M 0.89M 7.12M 7.77M
Net tangible assets - - - 5.48M 6.95M
Short term investments 0.09M 0.09M 0.04M 0.04M 0.04M
Net receivables 0.06M 0.06M 0.04M 0.07M 0.08M
Inventory 0.02M 0.07M - 2.77M -
Accounts payable 0.33M 0.53M 0.21M 1.33M 0.28M
Accumulated other comprehensive income 7.11M 5.41M 5.09M 6.14M 3.14M
Non currrent assets other - - 0.35M - -
Non current assets total 1.02M 1.02M 0.63M 0.58M 0.67M
Capital lease obligations 0.16M - - 0.08M 0.17M
Long term debt total - - - 0.00M 0.08M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -0.08M -0.10M -0.03M
Change to liabilities - - - 0.00M -0.55M
Total cashflows from investing activities -0.02M -0.58M -0.08M -0.10M -0.03M
Net borrowings -1.17M - - -0.09M -0.01M
Total cash from financing activities 7.22M 4.19M 2.80M 3.63M 11.85M
Change to operating activities - - - -0.08M 0.07M
Net income -5.93M -3.83M -6.86M -8.22M -6.32M
Change in cash 1.96M 0.69M -3.41M -3.43M 5.32M
Begin period cash flow 1.40M 0.71M 4.12M 7.55M 2.23M
End period cash flow 3.36M 1.40M 0.71M 4.12M 7.55M
Total cash from operating activities -5.23M -2.92M -6.14M -6.96M -6.21M
Issuance of capital stock 9.03M - 3.02M 3.74M 12.32M
Depreciation 0.19M 0.20M 0.20M 0.19M 0.10M
Other cashflows from investing activities - -0.56M - - -
Change to inventory 0.01M 0.01M 2.77M -2.77M -2.77M
Change to account receivables -0.02M 0.38M 0.03M 0.91M 0.07M
Sale purchase of stock -0.54M 3.50M -0.12M -0.02M -0.47M
Other cashflows from financing activities -0.11M 1.00M -0.09M -0.09M -0.01M
Change to netincome - - - 3.00M 2.61M
Capital expenditures 0.03M 0.02M 0.08M 0.10M 0.03M
Change in working capital 0.03M 0.36M 1.57M 3.32M 2.45M
Stock based compensation - 0.35M -1.05M - -
Other non cash items 0.48M -0.00M -1.05M - 6.21M
Free cash flow -5.26M -2.94M -6.22M -0.10M -6.24M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RHY
RHYTHM Biosciences Ltd		 -0.00
1.43%		 0.07 - - 14.23 6.13 223.83 -11.09
SHL
Sonic Healthcare Ltd		 0.18
0.91%		 20.06 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 0.01
0.58%		 1.74 28.83 15.24 0.82 0.97 1.52 9.49
ACL
Australian Clinical Labs Ltd		 0.04
1.25%		 3.24 26.67 16.84 0.81 3.95 1.24 5.12
HLS
Healius Ltd		 0.01
1.01%		 0.50 - 29.24 0.26 2.08 0.94 10.14

Profile*

RHYTHM Biosciences Ltd

Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

Bio21 Institute, Parkville, VIC, Australia, 3010

61 3 8256 2880

https://rhythmbio.com

Name Title Year Born
Mr. Otto Leslie-Steven Buttula AIMM, B.Ec., Grad. Dip., MAICD Exec. Chairman 1964
Mr. Glenn Gilbert MD, CEO & Director NA
Dr. Trevor John Lockett Ph.D. Technical Director, Chair of the Clinical Advisory Board & Exec. Director NA
Mr. Paul Smith Chief Financial Officer & Joint Company Sec. NA
Ms. Andrea Steele LLB B Com LLM Gen. Counsel & Company Sec. NA
Ms. Elena Deak Chief Commercial Officer NA
Mr. Otto Leslie-Steven Buttula AIMM, B.Ec., Grad. Dip., MAICD Executive Chairman 1964
Mr. Guy Carisbrooke Financial Controller NA
Ms. Andrea Steele LLB B Com LLM General Counsel & Joint Company Secretary NA
Mr. James Stephen Barrie CPA Joint Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…